Gulf Pharmaceutical Industries Stock

Equities

JULPHAR

AEG000201018

Pharmaceuticals

Market Closed - Abu Dhabi Securities Exchange 06:55:00 2024-04-17 am EDT 5-day change 1st Jan Change
0.963 AED -0.21% Intraday chart for Gulf Pharmaceutical Industries -3.70% +25.23%
Sales 2024 * 1.69B 461M Sales 2025 * 1.8B 490M Capitalization 1.11B 303M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.12 x
Net Debt 2024 * 780M 212M Net cash position 2025 * - 0 EV / Sales 2025 * 0.62 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 2,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 30.76%
More Fundamentals * Assessed data
Dynamic Chart
Gulf Pharmaceutical Industries Shares to be Suspended Ahead of Annual General Meeting MT
Abu Dhabi's Gulf Pharmaceutical Industries Resumes Trading Following FY23 Results Publication MT
Gulf Pharmaceutical Industries' FY23 Attributable Loss Widens; Revenue Up MT
Gulf Pharmaceutical Industries to Halt Trading During Board Meeting MT
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gulf Pharmaceutical Industries P.S.C. Approves Board Appointments CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer CI
Gulf Pharmaceutical Industries P.S.C. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Cigalah Group completed the acquisition of 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C.. CI
More news
1 day-0.21%
1 week-3.70%
Current month+1.26%
1 month-3.70%
3 months-22.96%
6 months+26.38%
Current year+25.23%
More quotes
1 week
0.96
Extreme 0.955
1.00
1 month
0.93
Extreme 0.926
1.04
Current year
0.75
Extreme 0.75
1.41
1 year
0.70
Extreme 0.701
1.41
3 years
0.70
Extreme 0.701
2.32
5 years
0.70
Extreme 0.701
2.79
10 years
0.70
Extreme 0.701
5.34
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 21-07-31
Director/Board Member - 16-12-31
Director/Board Member - 22-12-31
More insiders
Date Price Change Volume
24-04-17 0.963 -0.21% 304,260
24-04-16 0.965 -3.02% 4,439,921

Delayed Quote Abu Dhabi Securities Exchange, April 17, 2024 at 06:55 am EDT

More quotes
Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Company’s subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.963 AED
Average target price
0.72 AED
Spread / Average Target
-25.23%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. JULPHAR Stock